Partnership to revolutionise cancer diagnostic
The ³ÉÈË´óƬ has partnered with medical technology company Sienna Cancer Diagnostics in an exclusive worldwide licencing agreement to develop a unique cancer probe with the potential to detect a sugar molecule only present in cancer cells.
³ÉÈË´óƬ and Griffith University researchers have engineered a unique protein – SubB2M -  that can detect cancer by using liquid biopsies, immunoassays, circulating tumor cell assays and PET imaging.
As part of the exclusive licence, Sienna will collaborate with the ³ÉÈË´óƬ and Griffith University’s Institute for Glycomics to provide the data needed to commercialise cancer screening and diagnostic assays based on SubB2M.
The first stage will focus on developing a biopsy assay for cancer screening and monitoring suitable for use in hospital pathology laboratories. It is anticipated that this will take 12-18 months to complete.
For more information see our Media Release.
For more information on SubB2MÂ contact:
Michael Muthig, Senior Commercial Manager, Innovation and Commercial Partners